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ABSTRACT 
Beyond improvement of glucose control, thiazolidinediones exert pleiotropic effects, which may contribute to 
some cardiovascular protection. PROactive ("PROspective pioglitAzone Clinical Trial In macroVascular 
Events") has provided valuable, although controversial, information on the impact of pioglitazone on 
cardiovascular outcomes in a high-risk population of patients with type 2 diabetes and established macrovascular 
disease. Since 2005, there has been much debate on the relative value of the statistically non-significant 10% 
reduction in the quite challenging primary composite endpoint (combining cardiovascular disease-driven and 
procedural events in all vascular beds) versus the statistically significant 16% decrease in the more robust and 
conventional main secondary endpoint (all-cause mortality, myocardial infarction, and stroke) observed with 
pioglitazone. Revisiting PROactive deserves much interest following the report of inconclusive results on 
cardiovascular efficacy and safety of rosiglitazone in RECORD, the withdrawal (limitation) of rosiglitazone 
because of cardiovascular safety concern, the recent publication of a statement positioning pioglitazone in type 2 
diabetes and the near availability of cheaper generics of pioglitazone. Although subanalyses may have more 
limited value from a statistical viewpoint, they nonetheless can provide valuable information on the drug 
efficacy/safety profile and clinical insights into which patients might benefit most (in terms of cardiovascular 
outcomes) from pioglitazone therapy. 
Keywords : Cardiovascular outcome ; Heart failure ; Glucose control ; Pioglitazone ; PROactive ; 
Thiazolidionedione ; Type 2 diabetes mellitus 
 
1.        Introduction 
Type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular (CV) events that carry a 
poor prognosis. Majority of patients with T2DM are insulin resistant and have associated metabolic 
abnormalities that are also significant CV risk factors [1]. Thiazolidinediones (TZDs), acting as agonists of 
peroxisome proliferator-activated receptor gamma (PPAR gamma), are currently the only available oral anti-
hyperglycaemic medications that reduce insulin resistance [2]. In addition to lowering blood glucose, TZDs have 
been shown to affect and reduce many surrogate markers of CV risk in patients with T2DM [3-6]. Especially, 
pioglitazone has the ability to address key features of the metabolic syndrome [5,7,8]. Beyond favourable effects 
on glucose metabolism and glucose control, pioglitazone has indeed positive effects on lipid metabolism, blood 
pressure, endothelial function, markers of silent inflammation (C-reactive protein) and adiponectin levels. All 
these observations paved the way to the initiation of large prospective placebo-controlled trials assessing the 
efficacy of TZDs on CV outcomes in patients with T2DM. 
PROactive ("PROspective pioglitAzone Clinical Trial In macroVascular Events") was the first CV outcomes 
study with a TZD. It was a prospective, randomized controlled trial in 5238 patients with T2DM who had 
evidence of macro-vascular disease [9,10]. Patients recruited were assigned to oral pioglitazone titrated from 15 
mg to 45 mg (n = 2605) or matching placebo (n = 2633), to be taken in addition to their glucose-lowering drugs 
and other medications [10]. The end of the trial was event-driven and the average time of observation was 34.5 
months. The aim of PROactive was to ascertain whether pioglitazone reduces macrovascular morbidity and 
mortality in high-risk patients with T2DM. Pioglitazone was associated with a numerical (not statistically 
significant) reduction in a quite complex primary composite endpoint that involved cerebral, cardiac, and 
peripheral vessels. Interestingly enough, piogliazone was associated with a significant reduction in a more 
limited, but also stronger and more conventional, so-called main secondary endpoint (composite of all-cause 
mortality, non-fatal myocardial infarction or MI, and stroke) [10]. 
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Immediately after the publication of PROactive in 2005, the interpretation of the available data was controversial 
[11-14]. Indeed, CV outcome results raised much discussion [11-13] and even suspicion [14]. A few years later, 
controversy still persists as most people consider that the balance of pioglitazone is positive [15-19] whereas 
other concludes that there is no prove that pioglitazone is cardioprotective [20]. The conclusion of a Cochrane 
Database Systematic Review was that the results of PROactive have to be regarded as hypothesis-generating and 
need confirmation [20]. 
Another controlled trial was published a few years later, which assessed the CV efficacy and safety of a TZD, 
RECORD ("Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 
2 Diabetes"). It was the only prospective randomized trial designed to specifically evaluate CV outcomes with 
rosiglitazone. This trial was of major interest after the publication of a meta-analysis of 42 trials showing that 
rosiglitazone was associated with a significant increase in the risk of MI and with an increase in the risk of death 
from CV causes that had borderline significance [21]. The data from RECORD were inconclusive about any 
possible harmful effect on MI, but rosiglitazone did not increase the risk of overall CV morbidity or mortality 
compared with standard glucose-lowering drugs [22]. However, the results were limited because of issues with 
study design and event adjudication. Therefore, the CV safety concern of rosiglitazone persisted and was even 
reinforced by observational data [23]. Consequently, the use of rosiglitazone was not recommended anymore in 
guidelines published in 2009 [24] and this TZD was withdrawn from the market in many countries (all European 
countries for instance) in 2010 while its clinical use was markedly limited in the United States of America [25]. 
A first critical appraisal of PROactive, comprising an extensive safety data set, as well as new insights into the 
impact of pioglitazone in different patient subpopulations, was published in 2008 [26]. An overview of all the 
key safety and tolerability characteristics associated with pioglitazone therapy in PROactive was published one 
year later [27]. However, there are at least three main reasons for revisiting PROactive. First, since that time, 
new results resulting from specific post hoc analyses have been available. Second, the withdrawal of 
rosiglitazone raises much suspicion on the pharmacological class of TZDs in general, especially regarding its CV 
safety in high-risk patients [17,28]. Third, a recent position statement of the American Diabetes Association 
(ADA) and the European Association for the Study of Diabetes (EASD) published an updated algorithm for the 
initiation and adjustment of therapy for the management of hyperglycaemia in T2DM [29]. According to this 
position statement, "pioglitazone appeared to have a modest benefit on cardiovascular events as a secondary 
outcome in one large trial involving patients with overt macrovascular disease". In the proposed algorithm, 
pioglitazone can be considered as a valuable alternative as monotherapy if metformin cannot be used (not 
tolerated or contraindicated), as dual combination therapy if monotherapy with metformin alone does not 
achieve/maintain a glycated haemoglobin (HbA1c) target or as triple combination therapy provided that oral 
agents with complementary mechanisms of action are used. Still now, the most relevant evidence-based data 
supporting the use of pioglitazone in T2DM can be found in PROactive. The aim of the present review paper is 
to revisit PROactive data by critically analysing various clinical outcomes and recent results in order to help 
physicians in their decision to use or not use pioglitazone for the management of T2DM. 
2.        Cardiovascular outcomes 
2.1.        Primary endpoint 
The investigators in PROactive chose a challenging primary composite endpoint that included events in multiple 
vascular beds (cerebral, cardiac, and peripheral), as well as both disease-related and procedural endpoints. 
Indeed, the primary endpoint was the composite of all-cause mortality, non fatal MI (including silent MI), stroke, 
acute coronary syndrome (ACS), endovascular or surgical intervention in the coronary or leg arteries, and 
amputation above the ankle. In an intention to treat analysis, 514 of 2605 patients in the pioglitazone group and 
572 of 2633 patients in the placebo group had at least one event in the primary composite endpoint (hazard ratio 
or HR = 0.90, 95% CI 0.80-1.02, P = 0.095) (Table 1). Thus, the between-treatment difference did not reach the 
level of statistical significance. However, this primary composite endpoint is rather heterogeneous as it 
comprises both cardiac and peripheral CV endpoints. When the individual components of the primarily 
endpoints are analysed separately, it appears that cardiac and cerebrovascular endpoints are positively influenced 
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Table 1 - Cardiovascular outcomes in various subgroups of the PROactive trial. Results are given as hazard 
ratios (HR) with 95% confidence intervals in patients receiving pioglitazone (Pio) vs patients receiving placebo 
(Pbo). NA, not available. See text for description of primary and main secondary endpoints. 




All-cause mortality Specific endpoint  
(see footnote) 
Reference 
Overall 2605 vs 2633 HR = 0.90, 0.80-1.02; HR = 0.84, 0.72-0.98; HR = 0.96, 0.78-1.18; HR = 0.82, 0.70-0.97; Dormandy et al., 2005 [10] 
and Wilcox et al. [32]  P = 0.095 P = 0.027 P = 0.68 P = 0.020a 
Previous myocardial 
infarct 
1230 vs 1215 HR = 0.88, 0.75-1.04; HR = O.81, 0.65-1.01; HR = 0.85, 0.63-1.15; HR = 0.72, 0.52-0.99; Erdmann et al. [34] 
 P = 0.135 P = 0.058 P = 0.2873 P = 0.045b  
Previous stroke 486 vs 498 HR = 0.78, 0.60-1.02; HR = 0.78, 0.58-1.06; HR = 0.96, 0.64-1.44; HR = 0.53, 0.34-0.85; Wilcox et al. [35] 
 P = 0.067 P = 0.110 P = 0.843 P = 0.0085c  
Presence of peripheral 
artery disease 
619 vs 655 HR = 1.09, 0.88, 1.34; HR = 0.88, 0.67, 1.16; HR = 1.02, 0.73, 1.43; HR = 1.58, 0.81, 3.12; Dormandy et al. [36] 
 P = 0.4344 P = 0.3738 P = 0.9145 P = 0.1820d  
Absence of peripheral 
artery disease 
1986 vs 1978 HR = 0.84, 0.72, 0.97; HR = 0.83, 0.69, 1.00; HR = 0.93, 0.72, 1.21; HR = 0.41, 0.15, 1.17; Dormandy et al. [36] 
 P = 0.0160 P = 0.0453 P = 0.6094 P = 0.0954d  
Presence of chronic 
kidney disease 
274 vs 323 HR = 0.75, 0.55-1.03; HR = 0.66, 0.45-0.98; HR = 0.75, 0.55-1.03; NA Schneider et al. [52] 
 P = NA P = NA P = NAe   
Absence of chronic 
kidney disease 
2292 vs 2265 HR = 0.94, 0.83-1.07; HR = 0.89, 0.75-1.05; HR = 1.09, 0.87-1.38; NA Schneider et al. [52] 
 P = NA P = NA P = NA   
Patients on insulin at 
baseline 
864 vs 896 HR = 0.86, 0.71-1.04; HR = 0.85, 0.67-1.08; NA NA Charbonnel et al. [56] 
 P = 0.1198 P = 0.1831    
Patients developing 
serious heart failure 
149 vs 108 HR = 0.72, 0.51-1.01; HR = 0.64, 0.44-0.95; HR = 0.71, 0.45-1.11; NA Betteridge et al. [26] 
 P = 0.059 P = 0.025 P = 0.14   
a Cardiovascular death, nonfatal myocardial infarction (MI) or nonfatal stroke. 
b Fatal/nonfatal MI (excluding silent MI). 
c Fatal/non fatal stroke. 
d Amputation. 
e Data given in the paper by Schneider et al. [52], but not correct (copy-paste of data concerning primary composite endpoint). In fact, 21 
deaths (7.7%) in pioglitazone group vs 44 deaths (13.6%) in the placebo group, leading to a HR of about 0.57. 
 
2.2.        Main secondary endpoint 
A so-called main secondary endpoint was defined by the authors of PROactive as the composite of all-cause 
mortality, non-fatal MI, and stroke [10]. Thereby, this main secondary endpoint only included disease endpoints 
and not procedural endpoints [11]. A total of 301 patients in the pioglitazone group and 358 in the placebo group 
reached this endpoint (HR = 0.84, 95% CI 0.72-0.98, P = 0.027) (Table 1) [10]. Thus, the between-treatment 
difference became statistically significant. The relative risk of all-cause death, MI, and stroke for pioglitazone 
versus placebo was similar regardless of the baseline use of nitrates, blockers of the renin-angiotensin system, or 
insulin, with HR ranging from 0.81 to 0.87 [30]. 
Strongly divergent interpretations regarding the valid use and the clinical significance of this main secondary 
endpoint have been published after the original publication of PROactive. 
The relative value of the primary and main secondary endpoints in PROactive has been already discussed [26]. 
For some authors ("supporters"), if procedure-related endpoints (coronary and especially leg revascularization) 
are excluded, the efficacy of pioglitazone in the prevention of all-cause mortality, non-fatal MI and stroke, in 
high risk patients with T2DM, is clearly shown by the study [26]. For other authors ("opponents"), in any case, 
all of the argument and discussion about the importance of the main secondary endpoint cannot negate the fact 
that the primary endpoint failed to reach significance. For clinical trialists, secondary endpoinds should only be 
considered meaningful when the primary endpoint is positive. Otherwise, in the face of a negative primary 
endpoint, secondary endpoints should only be considered exploratory or hypothesis generating. If so, the correct 
statistical interpretation of the study would be that it is negative [14]. It is presumably the reason why the results 
of PROactive have to be regarded as hypothesis-generating and need confirmation according to the conclusion of 
a Cochrane Database Systematic Review [20]. 
Interestingly, the same composite endpoint was evaluated in a meta-analysis of 19 trials randomized trials 
evaluating piogliazone in a total of 16,390 patients with T2DM. Study drug treatment duration ranged from 4 
months to 3.5 years. Death, MI, or stroke occurred in 375 of 8554 patients (4.4%) receiving pioglitazone and 450 
of 7836 patients (5.7%) receiving control therapy (HR, 0.82, 95% CI 0.72-0.94, P = 0.005). Progressive 
separation of time-to-event curves became apparent after approximately 1 year of therapy. Individual 
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components of the primary endpoint were all reduced by a similar magnitude with pioglitazone treatment, with 
HRs ranging from 0.80 to 0.92. The magnitude of the favourable effect of pioglitazone on ischemic events was 
homogeneous across trials of different durations, for different comparators, and for patients with or without 
established vascular disease [31]. 
2.3.       MACE as a composite endpoint 
Composite endpoints of major adverse CV events (MACEs) are standard measures for comparing treatment in 
large CV outcome studies. An analysis from PROactive evaluated the effects of pioglitazone on the prespecified 
MACE endpoint of CV death, nonfatal MI, or nonfatal stroke and on 6 post hoc MACE composites (various 
combinations of all-cause, CV, or cardiac mortality; plus nonfatal MI; plus nonfatal stroke; and/ or ACS) in 
patients with T2DM [32]. At final visit, 257 (9.9%) pioglitazone-treated and 313 (11.9%) placebo-treated 
patients had a first event that contributed to the principal MACE endpoint (CV death, nonfatal MI, or nonfatal 
stroke) (HR = 0.82, 95% CI 0.70-0.97, P = 0.0201). Such MACE endpoint slightly differs from the main 
secondary endpoint in the original paper of PROactive (see above) by using CV deaths instead of all-cause 
mortality. There were statistically significant differences in favour of pioglitazone in 5 of the other MACE 
endpoints (P < 0.05) and a trend to benefit in the sixth (P = 0.052), with HR of 0.79-0.83. Thus, in patients with 
advanced T2DM at high risk for CV events, pioglitazone treatment resulted in significant risk reductions in 
MACE composite endpoints. 
The results of PROactive have been supported by two subsequent studies (CHICAGO and PERISCOPE) 
examining the impact of pioglitazone on important surrogates of atherosclerosis, namely carotid intima/medial 
thickness and coronary atheroma volume as delineated with intravascular ultrasound [33]. 
Table 2 compares various clinical endpoints in the two large prospective randomized clinical trials with CV 
outcomes assessing the efficacy and safety of TZDs in patients with T2DM: PROactive comparing pioglitazone 
with placebo, on the one hand, and RECORD comparing rosiglitazone versus an active comparator (metformin 
or sulfonylurea), on the other hand. A significant reduction in a composite endpoint comprising CV deaths plus 
non fatal MI plus non fatal stroke was observed in PROactive (HR = 0.82,95% CI 0.70-0.97) but not in 
RECORD (HR = 0.93, 95% CI 0.74-1.15). A trend for a lower incidence of MI was observed with pioglitazone 
in PROactive whereas a trend for a higher incidence of MI with rosiglitazone was observed in RECORD. No 
differences were observed in all-cause deaths or CV deaths (Table 2). However, caution is required in absence of 
head-to-head comparison because of potential confounding factors such as differences between PROactive and 
RECORD in patient CV risk profile, baseline therapy, drug used as comparator and duration of follow-up. 
 
Table 2 - Comparison of several cardiovascular (CV) outcomes in PROactive with pioglitazone vs placebo and 
in RECORD with rosiglitazone vs metformin (MET) or sulfonylurea (SU). Results are given as number of events, 
hazard ratios (HR) and 95% confidence intervals (CI). CHF, congestive heart failure. NA, not available. 
Endpoints PROACTIVE 
BASELINE: any therapy 
Follow up = 2.8 years 
RECORD BASELINE: SU or MET Follow up 
= 5.5 years 
 Pioglitazone   
(n = 2605) 
Placebo 
(n = 2633)
HR (95% CI) Rosiglitazone    
(n = 2220) 
SU or MET  
(n = 2227) 
HR (95% CI) 
Composite endpointa 257 313 0.82 (0.70-0.97) 154 165 0.93 (0.74-1.15)
All-cause deaths 177 186 0.96 (0.78-1.18) 136 157 0.86 (0.68-1.08)
CV deaths 127 136 0.94 (0.74-1.20) 60 71 0.84 (0.59-1.18)
Myocardial infarction 119 144 0.83 (0.65-1.06) 64 56 1.14 (0.80-1.63)
Stroke 86 107 0.81 (0.61-1.07) 46 63 0.72 (0.49-1.06)
Serious CHF 149 108 1.41 (1.10-1.80) 61 29 2.1 (1.35-3.27) 
Fatal CHF 25 22 1.15 (0.65-2.03) 10 2 5 (NA) 
Data obtained from Dormandy et al. [10], Wilcox et al. [32] and Erdman et al. [38] for PROactive and from Home et al. [22] and Komjada et 
al. [40], for RECORD. 
a Cardiovascular mortality plus non fatal MI plus non fatal stroke. 
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2.4.       Myocardial infarction 
Of the total cohort from PROactive, the subgroup of patients who had a previous MI (1230 = pioglitazone; 1215 
= placebo) was evaluated using prespecified and post hoc analyses [34]. Pioglitazone had a statistically 
significant beneficial effect on the prespecified endpoint of fatal and nonfatal MI (28% risk reduction [RR]; P = 
0.045) and ACS (37% RR; P = 0.035). There was a 19% RR in the cardiac composite endpoint of nonfatal MI 
(excluding silent MI), coronary revascularization, ACS, and cardiac death (P = 0.033). The difference in the 
primary endpoint defined in the main PROactive study did not reach significance in the MI population (12% RR; 
P = 0.135) (Table 1). The conclusion was that in high-risk patients with T2DM and previous MI, pioglitazone 
significantly reduced the occurrence of fatal and nonfatal MI and ACS. 
2.5.        Stroke 
A subgroup analysis evaluated the risk of stroke and other CV outcomes in patients with (n = 984) and without 
(n = 4254) prior stroke [35]. In patients with previous stroke (486 = pioglitazone; 498 = placebo), there was a 
trend of benefit with pioglitazone for the primary endpoint of PROactive and for the main secondary endpoint 
(Table 1). Pioglitazone reduced fatal or nonfatal stroke (HR = 0.53, 95% CI 0.34-0.85; P = 0.0085) and CV 
death, nonfatal MI, or nonfatal stroke (HR = 0.72, 95% CI = 0.52-1.00; P = 0.0467). In patients without prior 
stroke, no treatment effect was observed for a first stroke. Thus, in this subgroup analysis from PROactive, 
pioglitazone markedly (almost by half) and significantly reduced the risk of recurrent stroke in high-risk patients 
with T2DM. 
2.6.        Peripheral artery disease 
In the total PROactive population, multivariate analysis showed that the presence of PAD at baseline 
significantly affected the outcome of the primary (HR = 1.48, 95% CI 1.26-1.72, P < 0.0001) and main 
secondary endpoints (HR = 1.35,95% CI = 1.10, 1.65; P = 0.0036) [10]. 
Therefore, CVD outcomes were compared according to the presence of PAD at baseline in a post hoc analysis 
[36]. Of the 5238 patients in PROactive, 1274 had PAD at baseline (619 = pioglitazone; 655 = placebo). Patients 
with PAD at baseline showed significantly higher rates of the primary endpoint, main secondary endpoint, all-
cause mortality (all P < 0.0001), and stroke (P = 0.0175) than those with no PAD at baseline. The risk of PAD 
alone was similar to that of MI alone. The presence of PAD increased the risk of all major CVevents. In patients 
with no PAD at baseline, the event rates of the primary endpoint (P = 0.0160), main secondary endpoint (P = 
0.0453), and acute coronary syndrome (P = 0.0287) were significantly lower with pioglitazone than with 
placebo. For unknown reasons, this beneficial effect of pioglitazone was not seen in patients with PAD at 
baseline (Table 1). The conclusion was that T2DM patients without PAD at baseline seemed to benefit more 
from pioglitazone treatment than the overall PROactive population. 
2.7.       Congestive heart failure 
Patients with New York Heart Association (NYHA) Class II-IV congestive heart failure (CHF) at screening were 
excluded from PROactive. Overall during the trial, 6% (149 of 2065) and 4% (108 of 2633) of those in the 
pioglitazone and placebo groups, respectively, were admitted to hospital with CHF; however, mortality rates 
from CHF did not differ between groups (Table 2) [10]. A post hoc, blinded, independent adjudication of 
investigator-reported serious CHF events (those requiring hospital admission) dismissed a small number of 
investigator-reported events and identified several new cases. However, the higher prevalence with pioglitazone 
than placebo was confirmed (5.5% vs 4.2%) [37]. These data were confirmed in the already mentioned meta-
analysis of 19 randomized trials, in which serious CHF was reported in 200 (2.3%) of the 8554 pioglitazone-
treated patients and 139 (1.8%) of the 7836 control patients (HR = 1.41; 95% CI 1.14-1.76, P = 0.002) [31]. 
A secondary paper specifically analysed all CHF cases to assess the effects of treatment on morbidity and 
mortality after reports of serious CHF [38]. A serious adverse event of CHF was defined as CHF that required 
hospitalization or prolonged a hospitalization stay, was fatal or life threatening, or resulted in persistent 
significant disability or incapacity. More pioglitazone (5.7%) than placebo patients (4.1%) had a serious CHF 
event during the PROactive study (P = 0.007). However, mortality due to CHF was similar (25 of 2605 [0.96%] 
for pioglitazone vs 22 of 2633 [0.84%] for placebo; P = 0.639) (Table 2). Among patients with a serious CHF 
event, subsequent all-cause mortality tended to be lower with pioglitazone (40 of 149 [26.8%] vs 37 of 108 
[34.3%] with placebo; P = 0.1338). Proportionately fewer pioglitazone patients with serious CHF went on to 
have an event in the primary (47.7% with pioglitazone vs 57.4% with placebo; P = 0.0593) or main secondary 
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endpoint (34.9% with pioglitazone vs 47.2% with placebo; P = 0.025) [38]. In the subgroup of patients who had 
a previous MI, the rates of CHF requiring hospitalization were 7.5% (92 of 1230 patients) with pioglitazone and 
5.2% (63 of 1215) with placebo. Again, fatal CHF rates were similar (1.4% with pioglitazone vs 0.9% with 
placebo) [34]. 
Independent clinical predictors for CHF events were identified by Cox regression in a post hoc analysis of the 
PROactive trial and were used for calculating a risk prediction score [39]. Overall, 233 of 4951 patients with 
available baseline data suffered a serious adverse CHF event during a mean follow-up of 34.5 months. Age, renal 
dysfunction, diuretic use, HbA1c, duration of diabetes, low-density lipoprotein (LDL)-cholesterol, heart rate, 
bundle branch block, microalbuminuria, previous MI and pioglitazone treatment were independent predictors of 
CHF. The score stratified well in subgroups defined by pioglitazone treatment, prior MI, obesity, poor glycaemic 
control and microalbuminuria. 
Thus, although the incidence of serious CHF was increased with pioglitazone versus placebo in the total 
PROactive population of patients with T2DM and macrovascular disease, subsequent mortality or morbidity was 
not increased in PROactive patients with serious CHF. It is noteworthy that, in a similar analysis, the risk of 
CHF and associated deaths was specifically analysed in the RECORD trial with rosiglitazone. In the 
rosiglitazone group, the risk of CHF death or hospitalization was doubled versus metformin or sulfonylurea: HR 
= 2.10, 95% CI, 1.35-3.27. An excess in CHF deaths was observed (10 vs 2), including four CHF deaths as first 
CHF events (Table 2) [40]. These data support a better safety profile of pioglitazone compared to rosiglitazone. 
In a meta-analysis of 94 clinical trials, the observed increase in incidence of non-fatal CHF with pioglitazone 
was not statistically significant when compared with placebo or an active comparator [odds ratio = 1.38,95% CI 
0.90-2.12) [41]. Despite an increase in fluid-related events, recent studies suggested that individuals with T2DM 
and CHF (NYHA grade I/II) can be treated with pioglitazone with appropriate monitoring and adjustment of 
CHF therapies [42]. 
2.8.       Varia 
Baseline 12-lead electrocardiographs available in 5231 of the 5238 participants of the PROactive trial were 
analysed for heart rate, heart rate corrected QT (cQT)-interval, presence of atrial fibrillation/flutter, left axis 
deviation, right and left bundle branch block [43]. The association of electrocardiographic signs with total 
mortality, the principal secondary composite endpoint (death, MI and stroke) and serious adverse CHF events 
was examined by Cox-regression analysis. Overall, 223 (4.3%) patients showed atrial fibrillation/flutter, 213 
(4.1%) patients had right bundle branch block, 111 (2.1%) patients had left bundle branch block and 706 (13.5%) 
patients had left axis deviation. In multivariate adjusted analyses, heart rate and cQT-interval were significantly 
associated with mortality, the composite secondary endpoint and CHF, whereas right and left bundle branch 
blocks were significantly associated with CHF only. Left axis deviation was associated with CHF and atrial 
fibrillation/flutter was associated with mortality and CHF in univariate but not multivariate analyses. Thus, 
easily assessable electrocardiographic signs such as heart rate, cQT-interval and bundle branch blocks were 
predictive for adverse outcome independently of multiple risk factor adjustment and should be considered in 
clinical care. 
Finally, a post hoc analysis of the PROactive study investigated the incidence of new onset ECG abnormalities 
in patients with T2DM and macrovascular disease [44]. The cumulative incidence during the mean trial follow-
up of 34.5 months based on all available post-baseline ECGs was 2.5% for atrial fibrillation, 1.5% for right 
bundle branch block, 1.0% for left bundle branch block and 2.4% for left axis deviation. Given the strong 
prognostic impact of these ECG abnormalities (see above) and substantial therapeutic consequences, these 
findings highlight the need to regularly assess ECG in this patient population to detect individuals at high risk of 
CV events. 
3.        Other clinical outcomes 
3.1.       Cancer 
A meta-analysis of data from large randomized controlled trials of intensified glycaemic control (PROactive plus 
UKPDS, ACCORD, VADT) suggested that cancer risk is not reduced by improving glycaemic control in T2DM 
[45]. In the whole cohort of PROactive, the comparative incidence of all malignancies was similar; however, 
more cases of bladder neoplasm (14 vs 5) and fewer cases of breast cancer (3 vs 11) were observed in the 
pioglitazone versus placebo arms of the study [10]. PROactive was the first trial that raised the question of a 
possible increase in bladder cancer risk with pioglitazone (RR = 2.36, 95% CI 0.91-6.13). 
Published in : Diabetes Research & Clinical Practice (2012) 
Status : Postprint (Author’s version) 
 
In a recent meta-analysis of five studies (including PROactive), pioglitazone was associated with a significantly 
higher risk of bladder cancer (RR = 1.17, 95% CI 1.03-1.32, P = 0.013) [46]. No relation between pioglitazone 
and bladder cancer was found for duration of therapy < 12months and cumulative dose < 28,000 mg. The RR for 
bladder cancer in subjects with 12-24months of pioglitazone use was 1.34 (95% CI 1.08-1.66, P = 0.008). The 
effect was even stronger for cumulative treatment duration > 24months (RR 1.38, 95% CI 1.12-1.70, P = 0.003). 
There was a significant risk for patients with cumulative dose > 28,000 mg (RR 1.58, 95% CI 1.12-2.06, P = 
0.001). In a retrospective cohort study using a nested case-control analysis, ever use of pioglitazone was 
associated with an increased rate of bladder cancer (RR = 1.83, 95% CI 1.10-3.05). Again, the rate increased as a 
function of duration of use, with the highest rate observed in patients exposed for more than 24 months (RR = 
1.99, 1.14-3.45) and in those with a cumulative dosage greater than 28 000 mg (RR = 2.54, 1.05-6.14) [47]. 
3.2.        Bone fractures 
In PROactive, a higher rate of bone fractures was observed among pioglitazone-treated female patients (5.1% vs 
2.5%) [27]. A meta-analysis of data from 10 randomized controlled trials (including PROactive) and from 2 
observational studies confirmed that long-term TZD use doubles the risk of fractures among women with T2DM, 
without a significant increase among men [48]. These data were confirmed in a case-control study [49]. 
Postmenopausal women taking TZDs and the subset of men taking both loop diuretics and TZDs were at 
increased risk for fractures. In postmenopausal women, risk was associated with higher TZD dose. No difference 
between rosiglitazone and pioglitazone was apparent. 
3.3.        Oedema and weight gain 
As in previous studies, pioglitazone was associated with typical, but manageable, increases in oedema (26.4% vs 
15.1% for placebo) and weight gain (mean change of +3.8 kg vs -0.6 kg for placebo) in the PROactive cohort 
[27]. 
A post hoc analysis of body weight and weight change in relation to outcome has been performed [50]. The 
lowest mortality was seen in patients with body mass index (BMI) 30-35 kg/m2 at baseline. In comparison to this 
(reference group), patients in the placebo group with BMI < 22 kg/m2 (HR = 2.96, 95% CI 1.27-6.86, P = 0.012) 
and BMI 22 to 25 kg/m2 (HR = 1.88, 95% CI 1.11-3.21, P = 0.019) had a higher all-cause mortality. Weight loss 
during the PROactive study was associated with increased total mortality (HR per 1% body weight: 1.13, 95% 
CI 1.11-1.16, P < 0.0001), with increased CV mortality, all-cause hospitalization and the composite of death, MI 
and stroke. In contrast, weight gain was not associated with increased mortality. Weight gain in patients treated 
with pioglitazone (mean +4.0 ± 6.1 kg) predicted a better prognosis (HR per 1% weight gain: 0.96, 95% CI 0.92-
1.00, P = 0.037) compared to patients without weight gain. Surprising, among patients with T2DM and CV co-
morbidity in PROactive, overweight and obese patients had a lower mortality compared to patients with normal 
weight. Weight loss but not weight gain was associated with increased mortality and morbidity. There may be an 
"obesity paradox" in patients with T2DM and CV risk. 
3.4.       Kidney function 
Background and human studies have shown that TZDs reduce urinary albumin and protein excretion and 
interfere with most of the pathogenentic pathways involved in the development and progression of diabetic 
nephropathy [51]. In PROactive, creatinine values remained constant in both groups throughout the study. 
Changes in microalbuminuria were similar in the two groups [10]. 
Patients with diabetes and chronic kidney disease (CKD) are at particularly high risk for CV disease. A post hoc 
analysis from PROactive investigated the relationship between CKD and incident CV outcomes in a population 
of patients with T2DM and documented macrovascular disease, as well as the effects of pioglitazone treatment 
on recurrent CV disease [52]. CKD, defined as an estimated glomerular filtration rate (GFR) < 60 ml/min per 
1.73 m2, was present in 597 (11.6%) of 5154 patients of PROactive. More patients with CKD reached the 
primary composite endpoint than patients without CKD (27.5% vs 19.6%; P < 0.0001). Patients with CKD were 
also more likely to reach the main secondary composite endpoint (all-cause mortality, MI, and stroke). Patients 
who had CKD and were treated with pioglitazone were less likely to reach this secondary endpoint (HR = 0.66, 
95% CI 0.45-0.98), but this association was not observed among those with better renal function (Table 1). 
However, and surprisingly, there was a greater decline in estimated GFR with pioglitazone (between-group 
difference 0.8 ml/min per 1.73 m2/year) than with placebo. Thus, PROactive confirmed that CKD is an 
independent risk factor for CV events and death among patients with diabetes and preexisting macrovascular 
disease. Patients who had CKD and were treated with pioglitazone were less likely to reach a composite 
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endpoint of all-cause death, MI, and stroke, independent of the severity of renal impairment. Nevertheless, 
according to a recent meta-analysis of clinical trials, whether the use of TZDs has a positive or a negative impact 
upon major CV and renal outcomes in diabetic patients remains an open, unanswered question [53]. 
4.        Metabolic outcomes 
4.1.       Glucose control 
Overall, the addition of pioglitazone uptitrated to 45 mg/day resulted in a 0.5% reduction in HbA1c (Table 3) 
[10]. As the diabetic population in PROactive was rather heterogeneous regarding glucose-lowering modalities 
at randomization, several post hoc analyses were performed to more specifically analyse the metabolic effects of 
pioglitazone in various subgroups separated according to baseline therapy. Intensifying an existing oral 
monotherapy regimen (metformin: n = 514; sulfonylurea: n = 1001) to a dual oral regimen by adding 
pioglitazone versus placebo resulted in sustained improvements in glycaemic control and reduced progression to 
insulin therapy [54]. In patients treated with metformin plus sulfonylurea combination therapy and not receiving 
insulin at baseline (n = 1314), significantly greater reductions in HbA1c and greater proportions of patients with 
HbA1c at target were noted with pioglitazone versus placebo, despite a decrease in the use of other oral glucose-
lowering agents. There was an approximate twofold increase in progression to permanent insulin use in the 
placebo group vs the pioglitazone group when added to combination therapy. The overall safety of the 
metformin-sulfonylurea-pioglitazone triple therapy was good [55]. Almost one third of the total population were 
receiving insulin at baseline. A rapid and sustained decrease in insulin dose was observed with pioglitazone 
versus a progressive increase with placebo. By study end, the mean insulin dose was lower with pioglitazone (42 
U/day vs 55 U/day with placebo, P < 0.0001). Nevertheless, a greater HbA1c reduction was observed with 
pioglitazone (Table 3). Thus, pioglitazone use in combination with insulin resulted in a sustained improved 
glycaemic control and allowed the treatment regimens to be simplified and the insulin doses reduced [56]. 
PROactive also confirmed that the combination insulin plus pioglitazone is well tolerated, an important piece of 
information because concern was raised previously regarding the safety of such a combination [57]. 
In conclusion, post hoc analyses of PROactive demonstrate that the addition of pioglitazone titrated up to 45 mg 
significantly reduces HbA1c levels by about 0.5% whatever baseline glucose lowering therapy, metformin alone, 
sulfonylurea alone, metformin-sulfonylurea combination or insulin (with or without oral agents). These 
favourable metabolic effects were sustained up to 2.8 years (Table 3). 
 
Table 3 - Impact of pioglitazone on glucose control in the various subgroups of PROactive. Results are 
expressed as mean ± SD or as number of patients (%). Differences between pioglitazone and placebo: all P < 
0.001. NA, not available. 




HbA1c < 7%  
(53 mmol/mol)  
n (% patients) 
Permanent use of insulin 
n (% patients) 
All treatments [10]    
Pioglitazone (n = 2605) -0.8 (-1.6 to -0.1)a NA 183/1741b (11) 
Placebo (n = 2633) -0.3 (-1.1 to 0.4)a NA 362/1737b (21) 
Metformin only [54]    
Pioglitazone (n = 253) -0.8 ± 1.2 156 (68.1) 8 (3.4) 
Placebo (n = 261) -0.3 ± 1.5 108 (46.8) 16 (6.5) 
Sulfonylurea only [54]    
Pioglitazone (n = 508) -0.9 ± 1.3 287 (64.1) 30 (6.3) 
Placebo (n = 493) -0.4 ± 1.3 166 (38.9) 67 (14.8) 
Metformin + sulfonylurea [55]    
Pioglitazone (n = 654) -0.9 ± 1.3 269 (46.4) 95 (15.5) 
Placebo (n = 660) -0.3 ± 1.4 152 (26.5) 190 (31.1) 
Insulin [56]    
Pioglitazone (n = 864) -0.93 ± NA 308 (41.7) 790 (81.4) 
Placebo (n = 896) -0.45 ± NA 188 (24.3) 881 (98.3) 
a 95% confidence interval. 
b In patients not receiving insulin at randomization. 
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4.2.       Lipid profile 
As previously discussed [26], subgroup analyses by baseline statin use in PROactive suggested that the benefit of 
pioglitazone on the composite of all-cause mortality, nonfatal MI, or stroke (main secondary endpoint in 
PROactive) was observed in patients not receiving a statin at baseline (HR = 0.77, 95% CI 0.64-0.93, P = 0.008), 
but was not evident in those receiving statins at baseline (HR = 0.97, 95% CI 0.75-1.26, P = 0.845) [26]. 
However, the interaction between baseline statin use and the effect of pioglitazone did not reach statistical 
significance for this endpoint (P = 0.1547), indicating that the effect of pioglitazone, relative to placebo, was 
similar regardless of baseline statin use or not [26]. 
In PROactive, as in CHICAGO and PERISCOPE, there was a sustained effect of pioglitazone on glycaemic 
control and, in addition, beneficial effects in reducing triglycerides and increasing high-density lipoprotein 
cholesterol (HDL)-cholesterol beyond that seen with concomitant statin therapy [33]. 
A post hoc study examined the effect of pioglitazone on triglycerides, HDL-cholesterol, and LDL-cholesterol 
levels in patients from PROactive to determine whether pioglitazone-induced lipid effects were altered by 
different baseline antihyperglycaemia medication or statin use [58]. Independent ofglucose-lowering agent and 
statin use, triglyceride levels decreased in all subgroups treated with pioglitazone (-9.9% to -12.3%), whereas 
little change was observed in placebo groups. HDL-cholesterol increased nearly twice as much with pioglitazone 
(18.1-20.3%) as with placebo (8.1-11.8%) across all subgroups. LDL-cholesterol increased moderately with 
pioglitazone (5.2-9.6%) compared with placebo (3.3-7.6%). Thus, long-term pioglitazone therapy led to durable 
improvements in triglyceride and HDL-cholesterol levels, irrespective of baseline antihyperglycaemia therapy or 
statin use. 
Because pioglitazone improved both glucose control and lipid profile in PROactive, an interesting question is to 
know which of the metabolic changes can best explain the reduction in CV events. Although pioglitazone 
treatment was associated with a decrease in HbA1c and an increase in HDL-cholesterol, only the change from 
baseline HDL-cholesterol predicted the CV outcome (χ2 = 28.89, P < 0.0001). No other variables, including 
HbA1c, triglycerides and systolic blood pressure, showed significant direct associations with CV outcome [59]. 
Pioglitazone and rosiglitazone have significantly different effects on plasma lipids independent of glycaemic 
control or concomitant lipid-lowering or other antihyperglycaemic therapy. Pioglitazone compared with 
rosiglitazone is associated with significant improvements in triglycerides, HDL-cholesterol, LDL particle 
concentration, and LDL particle size [60,61]. Such difference in lipid effects may at least partially explain the 
different CV risk profile between pioglitazone and rosiglitazone [15,62-66]. 
5.         Pharmacoeconomic evaluation 
The publication of PROactive provides a relevant platform upon which to base a detailed economic evaluation of 
the possible additional benefit of pioglitazone over and above current best treatment in patients with T2DM and 
severe CV disease. Pioglitazone improved CV outcome and reduced the need to add insulin to existing therapy, 
which may contribute to reduce further expenses [67]. 
The cost-effectiveness of adding pioglitazone to existing treatment regimens in patients with T2DM with a 
history of macrovascular disease who are at high risk of further CV events has been analysed for different 
countries: United Kingdom [68], United States of America [69], Switzerland [70] and Germany [71,72]. The 
incremental cost-effectiveness ratio (ICER) per quality-adjusted life expectancy (QALY) gained with 
pioglitazone vs placebo was pounds 4060 in UK [68], $44,105 in the US [69], CHF 60,596 in Switzerland [70], 
and €13,294 in Germany [71,72]. The addition of pioglitazone to existing therapy in patients with T2DM at high 
risk of further CV events was considered cost-effective and may represent good value for money by currently 
accepted standards in these countries. It is noteworthy that the loss of patent of pioglitazone, which is now 
genericable, will substantially reduce the cost of the drug and thereby reduce the ICER, thus further improving 
the cost-effectiveness of such therapy with a TZD in the future. 
6.         Lessons for the clinician and perspectives 
TZDs initially showed great promise as unique PPAR-gamma receptor-mediated oral therapy for T2DM and 
acting specific insulin sensitizers [2], but a host of serious side effects, primarily CV events for rosiglitazone 
[21], have limited their utility. Although TZDs are traditionally classed according to their target, they have 
different and sometimes conflicting clinical benefit and adverse event profiles. It is speculated that this is 
because of differing properties and specificities for the PPAR receptors (each of which targets specific genes) 
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[73]. This is most obvious in the different impact on CV outcomes between pioglitazone and rosiglitazone in 
prospective clinical trials (less MI in PROactive versus a trend for more MI in RECORD, for instance). A meta-
analysis of 16 observational studies that directly compared the risk of CV outcomes for rosiglitazone and 
pioglitazone among patients with T2DM, including 810,000 TZDs users, showed that rosiglitazone is associated 
with significantly higher odds of CHF, MI, and death relative to pioglitazone in real world settings [23]. 
However, pioglitazone may also be associated with several adverse events, including body weight gain, fluid 
retention, CHF, peripheral bone fractures (especially in women) and possibly bladder cancer. All these adverse 
events were detected in PROactive [27], and confirmed in real life [28,64]. Therefore, it is crucial to perform a 
risk-benefit analysis to determine what role pioglitazone should play in our current treatment of T2DM [28]. 
An important question is whether the results from the controlled trial PROactive may be transposed into clinical 
practice in real life. In other words, should we be "proactive" in prescribing TZDs [74] and what does PROactive 
mean for primary care physicians? [75] In an increasing competitive environment among glucose-lowering 
therapies, the place of pioglitazone, as monotherapy, dual therapy or triple therapy, in the management of T2DM 
has been nicely summarized in the recent ADA-EASD position statement [29]. 
7.        Conclusion 
Although severely criticized by some researchers or clinicians, PROactive is a landmark study that contains a lot 
of information of potential interest. The main criticism concerns a too heterogeneous composite primary 
endpoint, which combined both disease-driven and revascularization procedural endpoints, and endpoints such 
as foot amputation which maybe driven by confounding factors such as infection. Furthermore, because the final 
analysis of the trial was event-driven and because of the numerous various events included in the primary 
endpoint, the consequence was a probably too short duration of the study to draw clear-cut and definite 
conclusions about CV outcomes. Nevertheless, all post hoc secondary analyses that have been perfomed since 
the original publication of PROactive in 2005 confirmed the value of pioglitazone as a glucose-lowering agent 
(as oral monotherapy, dual therapy, triple therapy and even combination with insulin), with additive positive 
effects that may contribute to coronary and cerebrovascular protection. However, even if pioglitazone exerts 
cardioprotective action and has proven to be cost-effective in patients with T2DM and macrovascular disease, its 
clinical use may be limited by the occurrence of several adverse events. Thus, the clinician should balance the 
pro and contra of using pioglitazone considering the individual patient's characteristics (patient-centred strategy 
as recommended by the recent ADA-EASD position statement). 
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